Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M, Chang G, Xu W, Augsberger C, Grau M, Zapukhlyak M, Ilieva K, Landgraf K, Mangelberger-Eberl D, Yousefi K, Berning P, Kurz KS, Ott G, Klener P, Khandanpour C, Horna P, Schanzer J, Steidl S, Endell J, Heitmüller C, Lenz G.
Patra-Kneuer M, et al. Among authors: horna p.
Front Immunol. 2023 Jul 31;14:1220558. doi: 10.3389/fimmu.2023.1220558. eCollection 2023.
Front Immunol. 2023.
PMID: 37600821
Free PMC article.